RESUMO
The FGF23-Klotho signaling axis is known to exert anti-aging effects via calcium-phosphorus metabolism. In mice deficient in FGF23-Klotho signaling, however, the number of splenocytes is reduced. FGF23 is expressed in both bone and spleen, with regulation of its production differing in these organs. As FGF23-Klotho signaling may play an immunological role in the spleen, splenocytes in male C57BL/6J mice were assayed for expression of Klotho or FGF23 by flow cytometry and immunohistochemistry. Cells that expressed Klotho included CD45R/B220+ CD21/CD35+ CD1d+ CD43- marginal zone B cells. These cells also expressed FGF receptor 1, indicating that Klotho-positive B cells could respond to FGF23. Plasmacytoid dendritic cells (pDCs) with CD11c+ CD45R/B220+ CD11b- CD8α- were found to produce FGF23. Klotho-positive cells and FGF23-producing cells were present in close proximity to each other, suggesting that FGF23 produced by pDCs may act within a limited area. These findings indicate that FGF23-Klotho signaling could play a biological or immunological role in the spleen.
Assuntos
Fatores de Crescimento de Fibroblastos/metabolismo , Glucuronidase/metabolismo , Baço/metabolismo , Animais , Linfócitos B/metabolismo , Células Dendríticas/metabolismo , Fator de Crescimento de Fibroblastos 23 , Fatores de Crescimento de Fibroblastos/genética , Glucuronidase/genética , Proteínas Klotho , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Receptores de Fatores de Crescimento de Fibroblastos/genética , Receptores de Fatores de Crescimento de Fibroblastos/metabolismo , Baço/citologiaRESUMO
Hyperphosphatemia is a serious complication which has been linked with an increased risk of cardiovascular mortality in patients with chronic kidney disease. Especially in end stage renal disease (ESRD) patients, the nutritional disturbance due to strict phosphate restriction with protein restriction is certainly associated with patients' survival. Firstly, the aggressive phosphorus removal by blood purification modality is also important for the good control in serum phosphate level. Secondary, the active phosphate binder therapy is actual effective treatment for ESRD patients with hyperphosphatemia. Until recently, none of the available agents fulfilled the criteria of an ideal phosphate binders. However, several phosphate binder such as calcium carbonate, sevelamer hydrochloride, lanthanum carbonate and so on, are available in Japan. This review work is describing about the history and clinical manifestation of these phosphate binders.
Assuntos
Carbonato de Cálcio/uso terapêutico , Quelantes/uso terapêutico , Desenho de Fármacos , Hiperfosfatemia/tratamento farmacológico , Hiperfosfatemia/etiologia , Nefropatias/complicações , Poliaminas/uso terapêutico , Hidróxido de Alumínio , Resina de Colestiramina , Doença Crônica , Dieta com Restrição de Proteínas , Humanos , Resinas de Troca Iônica , Lantânio/uso terapêutico , Fósforo na Dieta/administração & dosagem , SevelamerRESUMO
In end-stage renal disease patients, various abnormalities of bone mineral metabolism adversely affect mortality. Hyperphosphatemia is known to adversely affect mortality and quality of life in chronic kidney disease patients and has been shown to be involved not only in the onset and progression of secondary hyperparathyroidism but also in vascular calcification. Thus, hyperphosphatemia is the main treatment target indicated in several guidelines for chronic kidney disease-mineral and bone disorder treatment. Phosphate binders are typically required for the management of hyperphosphatemia because dietary phosphorus restriction and phosphorus removal by hemodialysis alone are insufficient. We are able to prescribe five phosphate binders (calcium carbonate, sevelamer HCl, lanthanum carbonate (LaC), bixalomer, and ferric citrate) to Japanese hemodialysis patients. LaC is the most powerful noncalcium-containing phosphate binder for the treatment of hyperphosphatemia. In this chapter, we discuss the efficacy and safety of LaC, the safety of which has been under debate. In particular, we consider its toxic effects on the skeletal system. LaC is effective for hyperphosphatemia treatment in end-stage renal failure patients. It has been shown to be able to decrease serum fibroblast growth factor-23 levels. This result suggests that it may have beneficial effects on the cardiovascular system in patients undergoing renal replacement therapy. However, the effects of LaC remain obscure. Further investigations are required. No negative effects of LaC on bone metabolism or bone morphometry have been reported, but long-term clinical data are needed.
Assuntos
Hiperfosfatemia/tratamento farmacológico , Falência Renal Crônica/terapia , Lantânio/uso terapêutico , Osso e Ossos/patologia , Fator de Crescimento de Fibroblastos 23 , Fatores de Crescimento de Fibroblastos/sangue , Humanos , Hiperfosfatemia/sangue , Hiperfosfatemia/etiologia , Falência Renal Crônica/complicações , Lantânio/efeitos adversos , Lantânio/sangue , Fosfatos/sangue , Diálise Renal , Fatores de TempoRESUMO
A 29-year-old woman was diagnosed with Henoch-Schönlein purpura nephritis (HSPN) based on the presence of purpura and histopathological findings showing crescent formation, mesangial proliferation and IgA deposition in the glomerular mesangium. She was treated with high-dose steroids; however, the nephritic syndrome persisted. Therefore, we diagnosed her with steroid-resistant HSPN and decided to add treatment with cyclosphamide pulse therapy. After one year of treatment, the histopathological findings, including crescent formation and IgA deposition, improved, as confirmed on a renal biopsy, and the patient fulfilled the criteria for complete remission. Cyclophosphamide pulse therapy may be considered an effective treatment for intractable HSPN.